How To Use CPT Code 0120U

CPT 0120U describes a proprietary laboratory analysis (PLA) test known as the Lymph3Cx Lymphoma Molecular Subtyping Assay. This article will cover the description, official description, procedure, qualifying circumstances, appropriate usage, documentation requirements, billing guidelines, historical information, and examples.

1. What is CPT Code 0120U?

CPT 0120U can be used to report the Lymph3Cx Lymphoma Molecular Subtyping Assay, a Mayo Clinic Laboratory-Developed Test. This test analyzes a preserved biopsy tissue specimen to measure and sequence 58 genes. The results are combined with patient data to determine the likelihood of primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) in a patient.

2. Official Description

The official description of CPT code 0120U is: ‘Oncology (B-cell lymphoma classification), mRNA, gene expression profiling by fluorescent probe hybridization of 58 genes (45 content and 13 housekeeping genes), formalin-fixed paraffin-embedded tissue, algorithm reported as likelihood for primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) with cell of origin subtyping in the latter.’

3. Procedure

1. The lab analyst performs the Lymph3Cx Lymphoma Molecular Subtyping Assay on a formalin-fixed, paraffin-embedded (FFPE) tissue specimen.
2. Fluorescent probes are hybridized with the specimen mRNA to provide a profile of the activity of 58 genes (45 content and 13 housekeeping).
3. The lab analyst may perform additional steps such as cell lysis, extraction, amplification, and hybridization or detection.
4. The algorithmic analysis is carried out, which includes cell of origin subtyping for DLBCL.
5. The results are reported as a score to predict the likelihood of PMBCL and DLBCL in the patient.

4. Qualifying circumstances

CPT 0120U is used for patients with or suspected to have primary mediastinal B-cell lymphoma (PMBCL) or diffuse large B-cell lymphoma (DLBCL). The test is ordered by clinicians to help determine the need for additional treatments such as chemotherapy and radiation. The test measures the activity of multiple genes in cancerous cells to provide valuable information for treatment decisions.

5. When to use CPT code 0120U

CPT code 0120U should be used when reporting the Lymph3Cx Lymphoma Molecular Subtyping Assay. It should not be reported in conjunction with CPT code 0017M.

6. Documentation requirements

To support a claim for CPT 0120U, the following documentation is required:

• Indication for the test, such as suspicion of primary mediastinal B-cell lymphoma (PMBCL) or diffuse large B-cell lymphoma (DLBCL)
• Preserved biopsy tissue specimen
• Date of service
• Results of the Lymph3Cx Lymphoma Molecular Subtyping Assay

7. Billing guidelines

When billing for CPT 0120U, ensure that the test is performed by a clinical lab that offers the Lymph3Cx Lymphoma Molecular Subtyping Assay. Report one unit of CPT 0120U for a single specimen analyzed on a single date of service. Do not report CPT 0120U with any other CPT code.

8. Historical information

CPT 0120U was added to the Current Procedural Terminology system on October 1, 2019. There have been no updates to the code since its addition.

9. Examples

1. A preserved biopsy tissue specimen is analyzed using the Lymph3Cx Lymphoma Molecular Subtyping Assay to determine the likelihood of primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) in a patient.
2. The Lymph3Cx Lymphoma Molecular Subtyping Assay is performed on a formalin-fixed, paraffin-embedded (FFPE) tissue specimen to provide valuable information for treatment decisions in a patient with suspected lymphoma.
3. A clinician orders the Lymph3Cx Lymphoma Molecular Subtyping Assay to assess the need for additional treatments like chemotherapy and radiation in a patient with primary mediastinal B-cell lymphoma (PMBCL) or diffuse large B-cell lymphoma (DLBCL).
4. The Lymph3Cx Lymphoma Molecular Subtyping Assay is used to analyze the activity of 58 genes in cancerous cells and determine the likelihood of PMBCL and DLBCL in a patient.
5. A preserved biopsy tissue specimen undergoes the Lymph3Cx Lymphoma Molecular Subtyping Assay to aid in the diagnosis and treatment planning for a patient with suspected lymphoma.
6. The Lymph3Cx Lymphoma Molecular Subtyping Assay is performed on formalin-fixed, paraffin-embedded (FFPE) tissue to provide important insights into the presence of primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) in a patient.
7. A clinician utilizes the Lymph3Cx Lymphoma Molecular Subtyping Assay to determine the need for further treatment options, such as chemotherapy and radiation, in a patient with suspected lymphoma.
8. The Lymph3Cx Lymphoma Molecular Subtyping Assay analyzes a preserved biopsy tissue specimen to assess the likelihood of primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) in a patient.
9. A formalin-fixed, paraffin-embedded (FFPE) tissue specimen is subjected to the Lymph3Cx Lymphoma Molecular Subtyping Assay to guide treatment decisions for a patient with suspected lymphoma.
10. The Lymph3Cx Lymphoma Molecular Subtyping Assay is performed on a biopsy tissue specimen to provide valuable information on the presence of primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) in a patient.